Rivastigmine as a Symptomatic Treatment for Apathy in Parkinson’s Dementia Complex: New Aspects for This Riddle

Table 5

12-month NPI results. In the first and third rows it has been reported the within group comparison with baseline and with 6-month results.

Subitems NPI	Number of patients/48 (%) within groups; (12  months versus baseline); (12  months versus 6 months)	Frequency × severity	Caregiver distress; within groups; (12 months versus baseline); (12 months versus 6 months)
Hallucinations	15 (31%); (); (NS)	2	1; (NS); (NS)
Delusions	8 (17%); (); (NS)	1	1; (NS); (NS)
Agitation/aggression	3 (8%); (NS); (NS)	2	1; (NS); (NS)
Dysphoria/depression	19 (40%); (); (NS)	3	1; (); (NS)
Anxiety	21 (44%); (); (NS)	4	1; (); (NS)
Irritability	1 (2%); (); ()	3	1; (); (NS)
Disinhibition	0 (0%); (); ()	0	1; (); (NS)
Euphoria	0 (0%); (); ()	0	1; (); (NS)
Apathy	33 (69%); (); (NS)	8	8; (NS); (NS)
Aberrant motor behavior	1 (4%); (NS); (NS)	1	1; (); (NS)
Sleep behavior change	5 (10%); (); (NS)	3	2; (); (NS)
Appetite change	1 (2%); (); (NS)	1	1; (); (NS)